Expression of PH-20 in normal and neoplastic breast tissue

被引:56
作者
Beech, DJ [1 ]
Madan, AK [1 ]
Deng, N [1 ]
机构
[1] Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA
关键词
hyaluronidase; breast cancer; neoplasm; PH-20;
D O I
10.1006/jsre.2002.6351
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Tumor metastasis involves a sequence of interrelated steps, of which penetration beyond the basement membrane is an essential component. Hyaluronic acid (HA) is a major structural component of the complex proteoglycans found in extracellular matrices and basement membranes. Hyaluronidase (PH-20) degrades HA, resulting in the disruption of basement membrane integrity and possible tumor dissemination. Materials and methods. Total RNA was extracted from samples (n = 51) of normal breast tissue (n = 12), ductal carcinoma in situ (DCIS) (n = 12), infiltrating ductal breast adenocarcinoma (n = 13), and metastatic breast cancer to lymph nodes (n = 14). RT-PCR was used to determine the relative level of PH-20 in each specimen. Results. PH-20 was detected in 41/51 (80.4%) of the specimens evaluated. PH-20 was present in 12/12 (100%) normal breast tissues; 8/12 (66.7%) DCIS; 13/13 (100%) invasive breast cancers; and 8/14 (57.1%) metastases. Of those specimens in which PH-20 was detected, there were increased levels of PH-20 in metastatic breast cancer to lymph nodes compared to D and invasive breast cancer. Stratification of specimen by race revealed that African American women had higher levels of PH-20 with invasive and metastatic beast cancer. Conclusions. Increased levels of PH-20 are noted in invasive and metastatic breast cancer compared to DCIS. Tumors from African American women with invasive and metastatic breast cancer demonstrated higher levels of PH-20 than Caucasians. Varying levels of PH-20 in mammary tissue may contribute to early invasion and metastasis of breast cancer. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:203 / 207
页数:5
相关论文
共 15 条
[1]   Cancer statistics 2001:: Quo vadis or whither goest thou? [J].
Bal, DG .
CA-A CANCER JOURNAL FOR CLINICIANS, 2001, 51 (01) :11-14
[2]  
CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO
[3]  
2-H
[4]  
FRASER JRE, 1989, CIBA F SYMP, V143, P41
[5]   PH-20 - A novel tumor marker for laryngeal cancer [J].
Godin, DA ;
Fitzpatrick, PC ;
Scandurro, AB ;
Belafsky, PC ;
Woodworth, BA ;
Amedee, RG ;
Beech, DJ ;
Beckman, BS .
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2000, 126 (03) :402-404
[6]   Cancer statistics, 2001 [J].
Greenlee, RT ;
Hill-Harmon, MB ;
Murray, T ;
Thun, M .
CA-A CANCER JOURNAL FOR CLINICIANS, 2001, 51 (01) :15-36
[7]  
LUI D, 1996, P NATL ACAD SCI USA, V93, P7832
[8]  
Madan AK, 1999, ONCOL REP, V6, P607
[9]  
Madan AK, 1999, ONCOL REP, V6, P1431
[10]  
Mustafa IA, 1997, ARCH SURG-CHICAGO, V132, P384